Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.38 |
| ▸ | TSHR | P16473 | 3/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | KDM1A | O60341 | 4/20 | 0.33 |
| ▸ | KDM1B | Q8NB78 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | CASP7 | P55210 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.33 |
| ▸ | CASP1 | P29466 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL238421 | 0.82 | KDM1A (0.44) | ALDH1A1TSHRCYP3A4MAPK1GAA | |
| SCHEMBL525424 | 0.82 | ALDH1A1 (0.47) | ALDH1A1TSHRCYP3A4MAPK1GAA | |
| SCHEMBL30695922 | 0.75 | ALDH1A1 (0.41) | ALDH1A1TSHRCYP3A4MAPK1MAPT | |
| SCHEMBL5306395 | 0.75 | ALDH1A1 (0.41) | ALDH1A1TSHRCYP3A4MAPK1MAPT | |
| SCHEMBL29664557 | 0.75 | NQO2 (0.32) | KDM1AKDM1B | |
| SCHEMBL29863733 | 0.75 | RAPGEF4 (0.40) | MAPK1KDM1AKDM1B | |
| SCHEMBL13550059 | 0.75 | NQO2 (0.32) | KDM1AKDM1B | |
| SCHEMBL1043169 | 0.75 | RAPGEF4 (0.40) | MAPK1KDM1AKDM1B | |
| SCHEMBL20843494 | 0.75 | ALDH1A1 (0.43) | ALDH1A1TSHRCYP3A4MAPK1GAA | |
| SCHEMBL15573628 | 0.75 | ALDH1A1 (0.41) | ALDH1A1TSHRCYP3A4MAPK1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 133 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260085067-A1 | CYCLIC SULFONAMIDE RIBONUCLEOTIDE REDUCTASE (RNR) INHIBITORS AND USES THEREOF | BOUNDLESS BIO INC (US) | 2026-03-26 | — | — | US | disclosed |
| EP-4482579-B1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH LPA RECEPTOR ACTIVITY | LHOTSE BIO INC (US) | 2026-02-18 | — | — | EP | disclosed |
| US-12534453-B2 | Inhibitors of glycogen synthase 1 (GYS1) and methods of use thereof | MAZE THERAPEUTICS, INC. (US) | 2026-01-27 | — | — | US | disclosed |
| US-12516059-B2 | Pyrazolopyridine compounds and uses thereof | INCYTE CORPORATION (US) | 2026-01-06 | — | — | US | disclosed |
| US-20250388565-A1 | ESTROGEN RECEPTOR ALPHA DEGRADERS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. | 2025-12-25 | — | — | US | disclosed |
| US-12428375-B2 | Compounds and compositions for treating conditions associated with LPA receptor activity | LHOTSE BIO, INC. (US) | 2025-09-30 | — | — | US | disclosed |
| US-12391663-B2 | Isoindolinone compounds | MONTE ROSA THERAPEUTICS AG (CH) | 2025-08-19 | — | — | US | disclosed |
| US-12384778-B2 | Pyrazolopyridine compounds and uses thereof | INCYTE CORPORATION (US) | 2025-08-12 | — | — | US | disclosed |
| EP-4587437-A1 | CYCLIC SULFONAMIDE RIBONUCLEOTIDE REDUCTASE (RNR) INHIBITORS AND USES THEREOF | Boundless Bio, Inc. (US) | 2025-07-23 | — | — | EP | disclosed |
| EP-4543871-A1 | ESTROGEN RECEPTOR ALPHA DEGRADERS AND USE THEREOF | Relay Therapeutics, Inc. (US) | 2025-04-30 | — | — | EP | disclosed |
| EP-3107900-B1 | 5-BENZYLISOQUINOLEINE DERIVATIVES FOR THE TREATMENT OF CARDIOVASCULAR DISEASES | SERVIER LAB (FR) | 2017-11-15 | — | — | EP | disclosed |
| US-9809553-B2 | Isoquinoline compounds, a process for their preparation, and pharmaceutical compositions containing them | LES LABORATOIRES SERVIER (FR) | 2017-11-07 | — | — | US | disclosed |
| US-20170137385-A1 | ISOQUINOLINE COMPOUNDS, A PROCESS FOR THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | LES LABORATOIRES SERVIER (FR) | 2017-05-18 | — | — | US | disclosed |
| EP-2870143-B1 | TRIAZOLE COMPOUNDS AS ANTIVIRALS | HOFFMANN LA ROCHE (CH) | 2017-05-17 | — | — | EP | disclosed |
| EP-3107900-A1 | DERIVATIVES OF 5-BENZYLISOQUINOLINE FOR THE TREATMENT OF CARDIOVASCULAR DISEASES | Les Laboratoires Servier (FR) | 2016-12-28 | — | — | EP | disclosed |
| US-9487488-B2 | Sulfonamide compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2016-11-08 | — | — | US | disclosed |
| US-20150307454-A1 | Sulfonamide Compound | KALLYOPE, INC. | 2015-10-29 | — | — | US | disclosed |
| WO-2015124877-A1 | DERIVATIVES OF 5-BENZYLISOQUINOLINE FOR THE TREATMENT OF CARDIOVASCULAR DISEASES | LES LABORATOIRES SERVIER (FR) | 2015-08-27 | — | — | WO | disclosed |
| EP-2896613-A1 | SULFONAMIDE COMPOUND | Mitsubishi Tanabe Pharma Corporation (JP) | 2015-07-22 | — | — | EP | disclosed |
| WO-2013029338-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2013-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12384778-B2 | Pyrazolopyridine compounds and uses thereof | PDXK, PCK1, PGK1 | ALDH1A1 2205/4885TSHR 4733/4885CYP3A4 1456/4885 |
| US-12391663-B2 | Isoindolinone compounds | CYP4F2, AOC2, AOC3 | ALDH1A1 1142/4885TSHR 1114/4885CYP3A4 684/4885 |
| US-20250388565-A1 | ESTROGEN RECEPTOR ALPHA DEGRADERS AND METHODS OF USE THEREOF | ESRRA, ESRRB, ESR2 | ALDH1A1 1679/4885TSHR 68/4885CYP3A4 672/4885 |
| US-20260085067-A1 | CYCLIC SULFONAMIDE RIBONUCLEOTIDE REDUCTASE (RNR) INHIBITORS AND USES THEREOF | RRM1, RRM2B, RRM2 | ALDH1A1 998/4885TSHR 76/4885CYP3A4 1636/4885 |
| US-12534453-B2 | Inhibitors of glycogen synthase 1 (GYS1) and methods of use thereof | GYS1, GYS2, GBA1 | ALDH1A1 2276/4885TSHR 3968/4885CYP3A4 3399/4885 |
| US-20170137385-A1 | ISOQUINOLINE COMPOUNDS, A PROCESS FOR THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | MYLK, MYLK2, MYLK3 | ALDH1A1 3415/4885TSHR 4698/4885CYP3A4 1738/4885 |
| US-20150307454-A1 | Sulfonamide Compound | TRPM8, TRPM5, TRPM7 | ALDH1A1 2634/4885TSHR 799/4885CYP3A4 1795/4885 |
| US-12428375-B2 | Compounds and compositions for treating conditions associated with LPA receptor activity | LPAR2, LPAR1, LPAR6 | ALDH1A1 1863/4885TSHR 1333/4885CYP3A4 4716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.